WO2003055500A8 - Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis - Google Patents

Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis

Info

Publication number
WO2003055500A8
WO2003055500A8 PCT/ES2003/000002 ES0300002W WO03055500A8 WO 2003055500 A8 WO2003055500 A8 WO 2003055500A8 ES 0300002 W ES0300002 W ES 0300002W WO 03055500 A8 WO03055500 A8 WO 03055500A8
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
prevention
treatment
pharmaceutical compositions
salt
Prior art date
Application number
PCT/ES2003/000002
Other languages
English (en)
French (fr)
Other versions
WO2003055500A1 (es
Inventor
Lousame Dolores Blanco
Fernandez Alvaro Acebron
Original Assignee
Italfarmaco Sa
Lousame Dolores Blanco
Fernandez Alvaro Acebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Sa, Lousame Dolores Blanco, Fernandez Alvaro Acebron filed Critical Italfarmaco Sa
Priority to AU2003211610A priority Critical patent/AU2003211610A1/en
Publication of WO2003055500A1 publication Critical patent/WO2003055500A1/es
Publication of WO2003055500A8 publication Critical patent/WO2003055500A8/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica oral, en forma de comprimidos masticables, granulados efervescentes o comprimidos efervescentes, estable y con características técnicas y organolepticas mejoradas, conteniendo una sal de iones fluoruro, vitamina D y calcio elemental en forma de sal, junto a cantidades adecuadas de excipientes farmacéuticamente aceptables, útiles para el tratamiento o prevención de la osteoporosis u otras enfermedades óseas caracterizadas por la perdida de masa ósea.
PCT/ES2003/000002 2002-01-04 2003-01-03 Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis WO2003055500A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003211610A AU2003211610A1 (en) 2002-01-04 2003-01-03 Pharmaceutical compositions for the treatment or prevention of osteoporosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200017A ES2192136B1 (es) 2002-01-04 2002-01-04 Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
ESP200200017 2002-01-04

Publications (2)

Publication Number Publication Date
WO2003055500A1 WO2003055500A1 (es) 2003-07-10
WO2003055500A8 true WO2003055500A8 (es) 2004-04-29

Family

ID=8500130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2003/000002 WO2003055500A1 (es) 2002-01-04 2003-01-03 Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis

Country Status (3)

Country Link
AU (1) AU2003211610A1 (es)
ES (1) ES2192136B1 (es)
WO (1) WO2003055500A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti
MY144631A (en) 2004-05-24 2011-10-14 Nycomed Pharma As Particulate comprising a calcium-containing compound and a sugar alcohol
BRPI0511710B8 (pt) * 2004-06-01 2021-05-25 Nycomed Pharma As comprimido mastigável, sugável e deglutível contendo cálcio
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
JP5305374B2 (ja) 2005-02-03 2013-10-02 タケダ ニコメド エイエス カルシウム含有組成物の製造のための速い湿式凝集方法
DE602006001295D1 (de) 2005-02-03 2008-07-03 Nycomed Pharma As Schmelzgranulation einer zusammensetzung mit einer calziumhaltigen verbindung
JP5420907B2 (ja) 2005-12-07 2014-02-19 タケダ ニコメド エイエス 予備圧縮されたカルシウム含有化合物
US7968130B2 (en) 2006-01-11 2011-06-28 Mission Pharmacal Co. Calcium-enriched food product
SI2358374T1 (sl) 2008-11-17 2014-01-31 Takeda Nycomed As Izboljšana topna stabilnost tablet, ki vsebujejo kalcijev karbonat
WO2019004984A2 (en) * 2017-05-29 2019-01-03 Biofarma Ilac Sanayi Ve Ticaret A.S. PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
CN109288811B (zh) * 2018-11-27 2021-02-09 正大制药（青岛）有限公司 一种艾地骨化醇软胶囊及其制备方法
CN109568279B (zh) * 2018-12-28 2020-10-20 正大制药（青岛）有限公司 一种氟骨化醇片剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345265A (en) * 1963-10-09 1967-10-03 Kendall & Co Multiple layer tablet with calcium salt central core separated from soluble fluoride outer coating
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
US5228445A (en) * 1990-06-18 1993-07-20 Board Of Regents, The University Of Texas System Demonstration by in vivo measurement of reflection ultrasound analysis of improved bone quality following slow-release fluoride treatment in osteoporosis patients
AU7295696A (en) * 1995-10-27 1997-05-22 F. Hoffmann-La Roche Ag Pharmaceutical composition for treating osteoporosis
CN1177455A (zh) * 1996-09-26 1998-04-01 天津市红桥医院 加碘低钠钙盐
ITFI970184A1 (it) * 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US20020041902A1 (en) * 2000-09-29 2002-04-11 Steiner Gregory Gene Fluoride as a chemoprotective and chemotheraputic agent for cancer in mammals

Also Published As

Publication number Publication date
AU2003211610A1 (en) 2003-07-15
ES2192136A1 (es) 2003-09-16
WO2003055500A1 (es) 2003-07-10
ES2192136B1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
WO2004098617A3 (en) Controlled release composition containing a strontium salt
MY142046A (en) Rapid dissolution formulation of a calcium receptor-active compound
WO2001091734A8 (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
HK1102427A1 (en) Compositions comprising strontium and vitamin d and uses thereof
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
WO2003055500A8 (es) Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis
TW200637587A (en) Anti-caries oral care composition with xylitol
WO2004037768A3 (en) Phenethanolamine derivatives
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200519075A (en) Novel compounds
HK1090843A1 (en) Pharmaceutical compositions for healing wounds
WO2005115414A3 (en) Orally-administrable compositions comprising stable amorphous calcium carbonate
HK1070836A1 (en) Solid oral anti-tartar and anti-plaque compositions
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
EP1645263A4 (en) MOUTH CAVE COMPOSITION
AU2003295589A1 (en) Oral compositions which mask the salty taste of salts
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2005011639A3 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
WO2009087652A3 (en) Pharmaceutical compositions, comprising calcitriol and calcium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 165722

Country of ref document: IL

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP